Mark McKinlay, PhD, is Director for the Center for Vaccine Equity (CVE) sector which oversees all of The Task Force for Global Health’s vaccine-related work. In this role, Dr. McKinlay oversees The Task Force’s work to increase access to vaccines for influenza in developing countries and prepare them for the next pandemic. He also guides The Task Force’s work to help eradicate polio and eliminate viral hepatitis.

Prior to joining The Task Force, Dr. McKinlay was Co-founder, Chief Scientific Officer, and Senior Vice President for Research and Development of TetraLogic Pharmaceuticals based in Malvern, Pa. At TetraLogic, Dr. McKinlay led the team that discovered and developed a novel, best-in-class drug targeting the inhibitors of apoptotic proteins for the treatment of cancer.

Prior to TetraLogic, Dr. McKinlay Co-founded ViroPharma Inc. and served as Vice President of Research and Development. While there, he led the development of an antipicornavirus agent that culminated in the first clinical demonstration that an antiviral can affect the duration and severity of the common cold.

For nearly 15 years, Dr. McKinlay served in varying roles, including Senior Director of Virology and Oncopharmacology in the research group at Sterling Drug. There, he discovered a novel class of antipicornavirus agents and advanced three of these agents into clinical trials. While at Sterling Drug, he also demonstrated that oral delivery of an antipicornavirus agent was effective in treating poliovirus infections in mice.

Dr. McKinlay holds master’s and doctoral degrees from Rensselaer Polytechnic Institute, and completed a postdoctoral research fellowship in virology at The Johns Hopkins University School of Hygiene and Public Health. He received his undergraduate degree from Union College.